A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Launched by DICE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF ELI LILLY AND COMPANY · Sep 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called LY4100511 (also known as DC-853) for adult patients who have moderate-to-severe plaque psoriasis, a common skin condition that causes red, scaly patches. The main goal of the study is to find out how safe this treatment is and how well it works in reducing the symptoms of psoriasis. The trial is currently looking for participants who are between the ages of 18 and 65, have been diagnosed with plaque psoriasis for at least six months, and meet certain health criteria.

If you decide to participate, you'll need to stop using other psoriasis treatments before starting the study and avoid sun exposure during the trial. Participants will be monitored closely for their skin condition and overall health throughout the study. It's important to note that certain individuals, such as those with specific types of psoriasis or other inflammatory conditions, may not be eligible to join. This study could be a valuable opportunity for those looking for new treatment options for their psoriasis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization
• • Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
• • Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.
• • Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study
• Exclusion Criteria:
• • Have had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.
• • Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.
• • Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.
• • Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).
• • Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.